Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Shares Outstanding (Weighted Average) (2016 - 2026)

Organogenesis Holdings has reported Shares Outstanding (Weighted Average) over the past 11 years, most recently at $126.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 3.75% year-over-year to $126.7 million; the TTM value through Dec 2025 reached $126.7 million, down 3.75%, while the annual FY2025 figure was $126.7 million, 3.75% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $126.7 million at Organogenesis Holdings, roughly flat from $126.9 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $132.3 million in Q3 2024 and troughed at $126.3 million in Q1 2025.
  • A 5-year average of $129.6 million and a median of $129.6 million in 2022 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 22.72% in 2021 and later dropped 4.22% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $128.3 million in 2021, then grew by 1.36% to $130.1 million in 2022, then increased by 0.89% to $131.2 million in 2023, then grew by 0.34% to $131.7 million in 2024, then fell by 3.75% to $126.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ORGO at $126.7 million in Q4 2025, $126.9 million in Q3 2025, and $126.9 million in Q2 2025.